Summary
Goodwin Procter's Life Sciences practice is co-hosting a reception during the BIO 2012 Convention with PwC. Clients, prospects and friends of the firm will be attending for an evening of networking.
Related Content
- Big Molecule WatchFebruary 7, 2025
EU Biosimilar Regulatory and Launch Updates
- Big Molecule WatchFebruary 6, 2025
BioNTech Acquires Biotheus To Boost Oncology Strategy
- Life Sciences PerspectivesFebruary 6, 2025
Medtech M&A and VC Signal Positive Momentum Entering 2025
- Big Molecule WatchFebruary 6, 2025
Federal Circuit Affirms Injunction Against Samsung and Formycon in Aflibercept BPCIA Litigation
- Big Molecule WatchFebruary 6, 2025
FDA Accepts BLA for Shanghai Henlius Biotech’s HLX11, a Pertuzumab Biosimilar
- AlertFebruary 5, 2025
Preparing for EDGAR Next – New Requirements for All EDGAR Filers
- Big Molecule WatchFebruary 4, 2025
FDA Publishes Its First Draft Guidance On Use of Artificial Intelligence in the Development of Drugs and Biological Products
- Big Molecule WatchFebruary 3, 2025
FDA Approves Celltrion’s AVTOZMA (tocilizumab-anoh)
- Speaking EngagementsFebruary 28, 2025
Yale OCS STEM PhD Pathways: Navigating Career Paths in Patent Law with Miho Kaneko
- Awards and RankingsFebruary 6, 2025
Goodwin Paris Recognized by Chambers France 2025
- EventFebruary 5, 2025
Goodwin Rare Disease Symposium 2025
- Press ReleaseFebruary 4, 2025
Goodwin Advises Akero Therapeutics on the Closing of its $402.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Press ReleaseFebruary 3, 2025
Goodwin Advised Aclarion on the $4.7 Million Closing of Registered Direct Offering of Common Stock
- Press ReleaseFebruary 3, 2025
Goodwin Expands Antitrust Litigation Offering with the Arrival of Partner Alexandra Russell in Washington, D.C.
- Press ReleaseFebruary 3, 2025
Goodwin Advises Underwriters in Metsera’s $275 Million Initial Public Offering
- Press ReleaseJanuary 31, 2025
Goodwin Advises Royalty Pharma on $511 Million Sale of Morphosys Development Funding Bonds